Table 2.
Baseline and 6 months echocardiographic characteristics.
| ERA + riociguat + selexipag (n = 37) | ERA + PDE5i + selexipag (n = 155) | |||
|---|---|---|---|---|
| Characteristics | 0 month | 6 months | 0 month | 6 months |
| PASP, mmHg | 95.8 ± 23.8 | 96.8 ± 25.5 | 92.0 ± 32.1 | 86.6 ± 30.8* |
| TR | 4.8 ± 0.3 | 5.2 ± 0.5 | 4.8 ± 0.9 | 4.5 ± 0.7 |
| RA area, cm2 | 29.0 ± 11.3 | 27.8 ± 13.9 | 28.3 ± 15.6 | 27.0 ± 16.6 |
| RAP, mmHg | 16.3 ± 17.2 | 9.8 ± 6.0 | 11.2 ± 7.9 | 9.2 ± 4.8* |
| RV, cm | 4.9 ± 0.9 | 5.1 ± 1.3 | 5.2 ± 1.4 | 5.0 ± 1.4* |
| Sm, cm/s | 10.4 ± 3.5 | 10.9 ± 1.9 | 10.5 ± 2.6 | 10.7 ± 2.4 |
| LVEDD, mm | 33.6 ± 7.4 | 34.1 ± 5.5 | 35.5 ± 7.1 | 37.4 ± 6.7** |
| LVEF (%) | 78.3 ± 5.5 | 88.7 ± 6.1 | 80.1 ± 6.4 | 78.0 ± 7.9 |
| EI | 1.6 ± 0.4 | 1.7 ± 0.4 | 1.9 ± 0.7 | 1.8 ± 0.6** |
| TAPSE, cm | 1.6 ± 0.4 | 1.7 ± 0.4 | 1.6 ± 0.4 | 1.7 ± 0.7** |
| PE, n(%) | 16 (51.6) | 7 (46.7) | 49 (36.3) | 15 (19.0)* |
Note: Data are presented as n (%), mean ± standard deviation, and interquartile range.
Abbreviations: EI, eccentricity index; ERA, endothelin receptor antagonist; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; PASP, pulmonary arterial systolic pressure; PDE5i, phosphodiesterase 5 inhibitor; PE, pericardial effusion; RA right atrial area; RAP, right atrial pressure; RV, right ventricle; Sm, mitral annular peak systolic velocity; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
*
p < .05 versus 0 month.
**
p < .01 versus 0 month.